Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Multiple Myeloma × Dosage Forms × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Prostatic Neoplasms 1 Neurofibromatosis 1 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Advanced Solid Tumors 1

Interventions

Dexamethasone 272 Lenalidomide 153 Bortezomib 152 Cyclophosphamide 114 Melphalan 107 Calcium Dobesilate 107 fludarabine phosphate 70 carfilzomib 60 Peripheral Blood Stem Cell Transplantation 53 Whole-Body Irradiation 52 Granulocyte Colony-Stimulating Factor 52 Filgrastim 52 pomalidomide 51 Mycophenolic Acid 51 fludarabine 43 daratumumab 42 Tacrolimus 41 ixazomib 40 Busulfan 40 Thalidomide 36 Cyclosporine 31 dexamethasone acetate 26 Stem Cell Transplantation 26 Antilymphocyte Serum 25 dexamethasone 21-phosphate 22 plerixafor 20 auricularum 20 Prednisone 19 Etoposide 19 liposomal doxorubicin 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02939183 2024-09-26

INTREPID-1

Amgen

Phase 1 Completed

61 enrolled 28 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡